FDA Approves TREMFYA® for Ulcerative Colitis Treatment, Promising New Hope for Patients
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to severely active ulcerative colitis (UC). This chronic inflammatory condition affects …
FDA Approves TREMFYA® for Ulcerative Colitis Treatment, Promising New Hope for Patients Read More